Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Cathal Friel-led Poolbeg Pharma set to float on AIM

Thu, 17th Jun 2021 14:34

(Sharecast News) - Infectious disease specialist Poolbeg Pharma is to list on the London Stock Exchange's junior market, AIM, with a view to raising the funds needed to develop its product pipeline.
The outfit is the third life science firm from the Cathal Friel and Raglan Capital stable, alongside Amryt and Open Orphan.

Four days before, Open Pharma had announced its intention to distribute Orph Pharma Company Limited's share capital in specie.

"Poolbeg's approach to asset development should result in good licensing opportunities and excellent returns in a relatively short period of time with substantially less risk than the traditional biotech model and allow for regular investor newsflow," Poolbeg's non-executive chairman, Cathal Friel said.

Friel was also the executive chairman of Open Orphan.

The total addressable Infectious Disease market was put by Poolbeg at $250bn by 2025.

The company also noted how the estimated cost of the Covid-19 pandemic measured by lost economic output and reduced health amounted to 90% of US gross domestic product.

Its main asset was POLB 001, a Phase II ready small molecule immunomodulator for severe influenza.

The value of the addressable market for severe flu was put at $800m.

Poolbeg also had a vaccine discovery platform to seek out new vaccines which might generate "significant" shareholder value.

It also owned the PredictViral Biomarker platform for predicting severe disease, which the firm said held the "potential to transform the way infectious diseases are treated".

There was also a pipeline of further assets for acquisition post-IPO.
More News
11 Jan 2022 14:39

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

IN BRIEF: Amryt Pharma delists from AIM as trading shifts to New York

Read more
22 Nov 2021 11:37

Amryt to delist from AIM, concentrate on Nasdaq trading

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced its intention to cancel its shares from trading on AIM on Monday, with effect on 11 January.

Read more
9 Nov 2021 22:01

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

TRADING UPDATES: Shepherd Neame losses cut; Beximco to sell Covid pill

Read more
19 Oct 2021 15:54

Amryt Pharma granted another two US patents

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma updated the market on patents for its lead development candidate 'Oleogel-S10' on Tuesday, as well as its recently-acquired and third commercial product 'Mycapssa'.

Read more
14 Sep 2021 07:32

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

IN BRIEF: Amryt Pharma ups guidance again after Chiasma acquisition

Read more
6 Aug 2021 14:41

IN BRIEF: Amryt hikes guidance on record second quarter results

IN BRIEF: Amryt hikes guidance on record second quarter results

Read more
6 Aug 2021 12:02

Record second quarter sees Amryt lift guidance further

(Sharecast News) - Amryt Pharma reported record second quarter results on Friday, raising its full-year guidance, as revenue in the three months ended 30 June came in at $62.8m, up from $46.2m year-on-year.

Read more
29 Jul 2021 17:10

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

EXECUTIVE CHANGES: HL CFO to depart; Novacyt hires CEO from Amryt

Read more
3 Jun 2021 19:20

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

BUSINESS UPDATES: HSBC issues notes; discoverIE reports profit fall

Read more
3 Jun 2021 11:26

FDA grants Amryt's Oleogel-S10 priority review status

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma announced on Thursday that the United States Food and Drug Administration (FDA) has granted priority review status for the new drug application for 'Oleogel-S10', for the treatment of epidermolysis bullosa (EB).

Read more
2 Jun 2021 19:10

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

TRADING UPDATES: Block Energy 2020 revenue jumps; Kanabo loss narrows

Read more
5 May 2021 19:20

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

TRADING UPDATES: SIG in good start to 2021; Accsys taps EUR37 million

Read more
6 Apr 2021 14:54

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Read more
31 Mar 2021 11:50

Amryt completes rolling FDA submission for Oleogel-S10

(Sharecast News) - Commercial-stage biopharmaceutical company Amryt Pharma has completed the rolling submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for 'Oleogel-S10', it announced on Wednesday, for the potential treatment of cutaneous manifestations of junctional and dystrophic epidermolysis bullosa (EB).

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.